Oric Pharmaceuticals (ORIC) Stock
Clinical stage cancer company targeting treatment resistance. Here's the price, business snapshot, and what's worth knowing about Oric Pharmaceuticals in August 2026.
ORIC Pharmaceuticals is a clinical‑stage oncology company developing targeted therapies intended to overcome mechanisms of treatment resistance in cancer. The business focuses on small molecules and biologics designed to restore or enhance tumour sensitivity to established treatments. As a clinical-stage developer, ORIC’s prospects are closely tied to trial outcomes, regulatory decisions and partner collaborations rather than stable commercial revenues. The company carries typical biotech risks: clinical and regulatory uncertainty, high research and development burn, and potential dilution from future financings. With a market capitalisation around $1.22 billion, the stock can be volatile around data readouts or corporate news. Investors should view ORIC as a higher‑risk, speculative exposure to oncology innovation and consider time horizon, diversification and risk tolerance. This information is educational and general in nature, not personalised investment advice; consider consulting a financial adviser before making investment decisions.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ORIC Pharmaceuticals' stock with a target price of $18.8, indicating growth potential.
Financial Health
ORIC Pharmaceuticals has a reasonable book value and cash flow, indicating stability but room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts and regulatory milestones can re‑rate the stock, though results are binary and can move the share price materially.
Focused oncology play
ORIC targets mechanisms of treatment resistance, a meaningful clinical need, but commercial success depends on proving benefit versus existing therapies.
Higher‑risk profile
As a clinical‑stage biotech with R&D burn and possible future financing, the stock may be volatile — suitable for investors comfortable with speculative risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
